1. Phase I-II Study of Paclitaxel, Cisplatin, and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium
   J. Bellmunt et al, 2000, Journal of Clinical Oncology CrossRef
2. Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent
   Andrew M. Evens et al, 2004, Clinical Cancer Research CrossRef
3. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
   Jiusheng Deng et al, 2016, Oncotarget CrossRef
4. Sensitivity to Gemcitabine and Its Metabolizing Enzymes in Neuroblastoma
   Masahiro Ogawa et al, 2005, Clinical Cancer Research CrossRef
5. Hedgehog Suppresses Paclitaxel Sensitivity by Regulating Akt-Mediated Phosphorylation of Bax in EGFR Wild-Type Non-Small Cell Lung Cancer Cells
   Yun-Chieh Tu et al, 2022, Frontiers in Pharmacology CrossRef
6. Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients
   Ashraf Z. Badros et al, 2005, Journal of Clinical Oncology CrossRef
7. The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan
   Suzanne Trudel et al, 2007, Clinical Cancer Research CrossRef
8. Mechanisms of Cell Sensitization to α Radioimmunotherapy by Doxorubicin or Paclitaxel in Multiple Myeloma Cell Lines
   Stephane Supiot et al, 2005, Clinical Cancer Research CrossRef